Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $1,828 - $3,531
-360 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $8,037 - $105,176
-940 Reduced 72.31%
360 $4,000
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $66,430 - $90,990
-1,000 Reduced 43.48%
1,300 $106,000
Q2 2020

Aug 14, 2020

SELL
$44.04 - $80.69 $149,075 - $273,135
-3,385 Reduced 59.54%
2,300 $165,000
Q1 2020

May 15, 2020

BUY
$44.49 - $93.39 $208,435 - $437,532
4,685 Added 468.5%
5,685 $253,000
Q4 2019

Feb 14, 2020

BUY
$66.49 - $137.73 $66,490 - $137,730
1,000 New
1,000 $95,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $110M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.